Liquid biopsy is a check that examines deoxyribonucleic acid (DNA) and different molecules in a affected person’s blood to detect most cancers. Liquid biopsy performs a key position in early most cancers detection by offering a non-invasive technique for detecting the presence of most cancers cells within the physique.
This check can detect circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in sufferers’ blood, indicating the presence of most cancers earlier than signs seem or earlier than a tumor might be seen on imaging assessments.
This enables for earlier most cancers detection, resulting in earlier remedy and probably higher outcomes for sufferers. Moreover, liquid biopsy can be used to observe the development of most cancers and assess the effectiveness of remedy, serving to make remedy choices and choice making to proceed or change remedy.
The healthcare business has rapidly embraced liquid biopsy know-how for its accuracy, velocity, and comfort. It’s utilized in many hospitals and clinics worldwide and is turning into an integral a part of the healthcare business. With its potential to detect most cancers in its early phases and with minimal discomfort to the affected person, it’s revolutionizing the best way healthcare professionals diagnose and deal with most cancers.
The group of professional analysts from the healthcare vertical at BIS Analysis has been learning the position of liquid biopsy in early most cancers detection and its influence on the general healthcare business, publishing a number of research across the identical.
BIS Analysis is internet hosting a webinar that can comprehensively view liquid biopsy.
Listed here are the main points:
Webinar Subject: Liquid Biopsy – An Rising Frontier in Early Multicancer Detection
Agenda: To know the next:
• Developments and key market developments
• Frequent methodologies employed in liquid biopsy evaluation
• Overview of rising medical purposes and the testing panorama
• Adoption situation and key investments
• Conclusion and future outlook
Causes to Attend the Webinar?
• To know the technological innovation in liquid biopsy
• To determine components limiting the liquid biopsy adoption in medical software
• To know how liquid biopsies could assist with remedy choice and monitoring of most cancers remedy outcomes
• To discover market alternatives in numerous areas
Our eminent panelists for this webinar can be:
Azeet Narayan – Azeet Narayan is a Principal Scientist in Sema4. His important pursuits lie in growing sequencing-based modern diagnostic assays to allow ultra-sensitive detection of nucleic acid biomarkers in medical samples. His analysis curiosity consists of numerous fields of bodily and bio-chemical sciences geared toward attaining life like diagnostic options for difficult ailments.
Nitish Kumar – Nitish Kumar is the principal advisor throughout the healthcare unit of BIS Analysis. He has a postgraduate diploma in pharmaceutical sciences and over eight years of expertise managing biopharma, life sciences, and biotechnology domains. Nitish has a profitable monitor file of consulting Fortune 500 purchasers within the bio-pharmaceuticals and life sciences area. He’s skilled in making ready epidemiological-based knowledge fashions for biopharmaceutical merchandise.
Riya Gupta – Riya Gupta is a analysis analyst throughout the healthcare unit of BIS Analysis. Within the present position, Riya is accountable for finishing up complete qualitative and quantitative market info, which incorporates market dynamics like sizing, development evaluation, brief and long-term market forecasting, and aggressive panorama evaluation of the precision medication business.
Timing and Registration:
The webinar goes to happen on January 24, 2023, on the following time:
• 9:00 A.M. (EST/EDT)
• 2:00 P.M. (GMP)
• 7:30 PM (IST)
Go to our web site and register for the occasion immediately. Get an edge over your opponents by studying the way forward for a sustainable area financial system.